Candel Therapeutics, Inc. CADL Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$54.42M-37.5% | -$38.18M+30.8% | -$22.76M+56.4% | -$22.14M+55.7% | -$39.58M-5.9% | ||
| $712K-20.0% | $808K-9.8% | $890K-1.1% | $890K-1.1% | $890K-1.1% | ||
| $4.96M+8.1% | $3.82M-28.1% | $3.77M-24.7% | $3.79M-15.9% | $4.58M+34.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $1.32M+4,348% | $272K— | ||
| —— | —— | —— | —— | -$27K— | ||
| —— | —— | —— | $1.64M+977% | -$440K+63.1% | ||
| $111.5K— | $178K— | —— | —— | —— | ||
| -$481K+8.6% | -$509K+0.8% | -$538K-7.6% | -$539K-10.5% | -$526K-10.7% | ||
| -$47.73M-75.5% | -$38.31M-41.8% | -$33.56M-17.2% | -$29.89M+3.1% | -$27.2M+14.6% | ||
| $1.26M+10,392% | $587K+3,569% | $181K+202% | $37K-77.3% | $12K-96.3% | ||
| —— | $27K— | —— | —— | —— | ||
| -$1.23M-10,167% | -$560K-3,400% | -$154K-285% | -$37K+74.1% | -$12K+96.1% | ||
| —— | —— | —— | —— | —— | ||
| $155.15M+65.6% | $59.47M-36.9% | $107.49M+4,686% | $109.16M+19,085% | $93.67M+6,907% | ||
| $102.82M+54.7% | $17.23M-74.4% | $70.41M+366% | $79.23M+360% | $66.45M+298% | ||
| $2.25M+50.2% | $1.28M-28.7% | $904K-55.2% | $1.2M-44.3% | $1.5M-31.8% | ||
| —— | —— | —— | —— | —— | ||
| $622K+169% | $360K+33.3% | $149K-51.0% | $190K-41.5% | $231K-30.2% | ||
| $712K-20.0% | $808K-9.8% | $890K-1.1% | $890K-1.1% | $890K-1.1% | ||
| -$481K+8.6% | -$509K+0.8% | -$538K-7.6% | -$539K-10.5% | -$526K-10.7% | ||
| $50K+214% | $24K+145% | $10K+183% | -$36K-257% | -$44K-160% | ||
| —— | —— | —— | $1.64M+977% | -$440K+63.1% | ||
| $143K+16.3% | $138K+16.0% | $133K+15.7% | $129K+16.2% | $123K+15.0% | ||
| $339K+19.8% | $321K+17.2% | $304K+14.7% | $293K+14.5% | $283K+14.1% | ||
| —— | $47.95M— | —— | —— | —— | ||
| —— | -$11.73M-28.0% | -$10M— | -$10M— | -$10M— | ||
| $158K— | $135K— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $93K— | —— | —— | —— | ||
| —— | —— | -$15.89M— | -$13.1M— | $5.93M— | ||
| $111.5K— | $178K— | —— | —— | —— | ||
| -$481K+8.6% | -$509K+0.8% | -$538K-7.6% | -$539K-10.5% | -$526K-10.7% | ||
| —— | $2.08M— | —— | —— | —— | ||
| -$48.99M-80.0% | -$38.9M-43.9% | -$33.74M-17.6% | -$29.93M+3.5% | -$27.21M+15.5% | ||
| -$48.99M-80.0% | -$38.9M-43.9% | -$33.74M-17.6% | -$29.93M+3.5% | -$27.21M+15.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Candel Therapeutics, Inc. generate?
- Candel Therapeutics, Inc. (CADL) generated -$47.7M in operating cash flow over the trailing twelve months.
- What is Candel Therapeutics, Inc.'s free cash flow?
- After $1.3M of capital expenditures, Candel Therapeutics, Inc.'s free cash flow was -$49.0M over the trailing twelve months, down 80.0% year over year.
- Where does Candel Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Candel Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
